News
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must ...
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
Zacks.com on MSN1h
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowZacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback